Original paper ‘Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA study’. Int J Clin Pract 2006; 60: 1364–70.
Since publication, an error has been spotted in table 2 which meant that the percentage symbol was excluded. The corrected table is detailed below.
Table 2.
Characteristics of the study population at baseline (n = 3175)
| Variables | |
|---|---|
| Biodemographic data | |
| Sex (male/female) (%) | M: 49 F: 51 |
| Age (years), mean ± SD | 63±10 |
| BMI (kg/m2), mean ± SD | M: 28.2±3.8 F: 28.3±4.2 |
| Waist circumference (cm), mean ± SD | M: 101.3 ± 12.2 F: 96.8±14.1 |
| Cardiovascular risk factors (%) | |
| Grade I hypertension | 43 |
| Grade II hypertension | 57 |
| Hypercholesterolemia | 32 |
| Current smoking | 30 |
| Family history cardiovascular disease | 16 |
| Diabetes mellitus | 15 |
| Target organ damage (%) | |
| Left ventricular hypertrophy | 18 |
| Atherosclerotic plaques | 7 |
| Mild renal impairment/microalbuminuria | 5 |
| Associated clinical conditions (%) | |
| Ischaemic heart disease | 10 |
| Peripheral arterial disease | 6 |
| Congestive heart failure | 4 |
| Renal failure | 4 |
| Cerebrovascular disease | 3 |
| Advanced retinopathy | 1 |
| Cardiovascular risk (%) | |
| Low risk | 7.5 |
| Medium risk | 44 |
| High | 22.7 |
| Very high | 25.8 |
| Clinical data (mean ± SD) | |
| SBP (mmHg) | 159.5 ± 11.7 |
| DBP (mmHg) | 95.2 ± 7.4 |
| Heart rate (bpm) | 68.4 ± 4.2 |
M, male; F, female; BMI, body mass index; SBP, systolic blood pressure; DPB, diastolic blood pressure.
Reference
- 1.Barrios V. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA study’. Int J Clin Pract. 2006;60:1364–70. doi: 10.1111/j.1742-1241.2006.01176.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
